CAC2 Childhood Cancer Community News Digest (May 30-June 5)

Assorted News from Last Week:

The Coalition Against Childhood Cancer is pleased to announce the 2022 Annual Summit hosted by Children’s Hospital of Philadelphia and presented by Day One Biopharmaceuticals.  This annual event reflects the CAC2 values and mission by providing top-notch educational programming, designing multiple opportunities for members to connect and engage, and showcasing the ongoing work of our members who are working for a future without childhood cancers.

A combination of brentuximab vedotin (Adcetris) and chemotherapy was safe and effective in pediatric patients (up to age 21 years) with newly diagnosed high-risk Hodgkin lymphoma.

Cancer in lymph nodes may help tumors spread by enlisting immune cells. Cancer cells “not only avoid attack in the lymph nodes, but they actually turn things completely around and somehow convince the immune system to help the tumor spread,” explained the study’s senior scientist, Edgar Engleman, M.D., of Stanford Medicine.

Upcoming Webinars, Online Opportunities, and Meetings:

The 20^th International Symposium on Pediatric Neuro-Oncology, ISPNO 2022 from 12 – 15 June 2022, and the Annual Meeting of the Brain Tumor Group of SIOP Europe (SIOPE-BTG) in Hamburg, Germany, from 11 – 12 June 2022.  Registration link.

Prime Stage for bringing awareness to childhood cancer and inspiring youth with their upcoming youth production based on Alex Scott (inspiration for CAC2 Member Alex’s Lemonade Stand Foundation), The Amazing Lemonade Girl, June 16-19 in Pittsburgh, PA.  The play, based on a book by Liz and Jay Scott, shows how a single person can change the world one act, or even one cup at a time.

Leukemia & Lymphoma Society will host a free virtual education program for families and caregivers of pediatric blood cancer patients on June 15 at 5:00 CDT. Participants will learn about immunotherapy options for children with Leukemia and Lymphoma. Participants will gain a better understanding about some of the most recent innovations in treating the most common leukemias and lymphomas of childhood. Attendees will be introduced to the field of immunotherapy in cancer treatment and gain insight into how novel therapies are conceived, tested and approved.  Registration link.

Children’s Cancer Cause is hosting a virtual externally-led Patient-Focused Drug Development (PFDD) meeting on Reducing Cardiac Late Effects in Pediatric Cancer Survivors, on September 15, 2022. The conference is an opportunity for survivors and caregivers to educate representatives of the FDA, academic researchers, and pharmaceutical companies about their personal experiences managing the impact of cardiac late effects on daily living and long-term health.  Registration link.

Take Action:

Children’s Cancer Cause has established an annual award, the Survivorship Champion’s Prize, to be presented to a group, program or institution making significant advances in programs and services to provide life-long health maintenance for survivors of pediatric cancers.  These awards recognize the importance of the unique challenges associated with the post-treatment services for survivors, especially as they transition to non-oncology adolescent and/or adult health care services.  This year, there are awards in two categories (click here for more information and to apply):

• Champion’s Prize Award: $10,000
• Recognition Awards for 1) Program Impact; 2) Collaboration; and 3) Scalability: $5,000 each

During June, on Childhood Cancer International social media wants to share stories, testimonials and activities regarding childhood cancer survivorship. If you have content that would like to share with us please send it to .